CDH13 and chronic myelogenous leukemia, BCR-ABL1 positive: CDH13 is highly methylated in cancers such as CML [11], non-small cell lung cancer [21], and breast cancer [22], resulting in a significant decrease in its expression level and the loss of biological functions of oncogenes (Fig. 1A).